RxDoctor Payments DataLook up a doctor →

William Skinner, MD

Medical Oncology · Paducah, KYNPI 1376657254

Payments from drug & device makers

$222,185in general payments, 2019–2025

Across 890 payments — averaging $249.65 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Pharmaessentia USA Corporation$91K
  • Incyte Corporation$35K
  • Bristol Myers Squibb$34K
  • Amgen$28K
  • Pharmacyclics LLC, An Abbvie Company$17K
  • Pfizer$4K
  • plus $13K from 54 others

What the payments were for

  • Consulting fees$3,22518%
  • Travel & lodging$1,4588%
  • Food & beverage$11,77865%
  • Education$1,2947%
  • Gifts$250%
  • Other$4663%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Pharmaessentia USA Corporation6$91,287
Incyte Corporation49$35,049
Bristol Myers Squibb32$34,159
Amgen51$27,671
Pharmacyclics LLC, An Abbvie Company98$17,450
Pfizer24$3,513
E.r. Squibb & Sons, L.L.C.45$1,336
Puma Biotechnology, Inc.11$1,189
Novartis43$1,050
Seagen Inc.36$861
AstraZeneca(2 entities)44$734
Johnson & Johnson(2 entities)52$726
Merck47$640
Sanofi26$468
Astellas Pharma US Inc13$407
Genentech USA, Inc.28$355
Beigene USA, Inc.13$266
Daiichi Sankyo Inc.15$259
Takeda Pharmaceuticals U.S.A., Inc.12$242
Gilead(2 entities)14$241
GSK13$240
Lilly USA, LLC9$235
Eisai Inc.13$207
Regeneron Healthcare Solutions, Inc.8$176
Secura Bio, Inc.6$145
Exelixis Inc.8$143
EMD Serono, Inc.8$142
Teleflex LLC1$139
Adaptive Biotechnologies Corporation6$134
Rigel Pharmaceuticals, Inc.8$129
Coherus Oncology, Inc.7$129
Tersera Therapeutics LLC8$127
Karyopharm Therapeutics Inc.7$121
AbbVie7$113
Ipsen Biopharmaceuticals, Inc7$113
Bayer6$109
Array Biopharma Inc7$106
Sirtex Medical Inc1$104
Boehringer Ingelheim6$100
Stemline Therapeutics Inc.4$86
Taiho Oncology, Inc.7$85
Tempus AI, Inc3$83
Alnylam Pharmaceuticals Inc.4$83
Novo Nordisk5$81
Mirati Therapeutics, Inc.4$73
Global Blood Therapeutics, Inc.4$66
Servier Pharmaceuticals LLC4$64
Macrogenics, Inc.3$60
Novocure Inc.4$59
Epizyme, Inc.4$59
Foundation Medicine, Inc.4$54
Teva Pharmaceuticals USA, Inc.4$53
EUSA Pharma (US) LLC1$41
Morphosys, US Inc.3$39
Blueprint Medicines Corporation2$37
G1 Therapeutics, Inc.2$35
Geron Corporation1$35
Acceleron Pharma, Inc.2$33
Kyowa Kirin, Inc.2$30
ADC Therapeutics America, Inc.2$29

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$222,185 in reported general payments places this provider in the 70th percentile of 53 medical oncology providers in Kentucky.

See all medical oncology providers in Kentucky

Medicare billing

Part B allowed, 2024
$138,872
Medicare patients
395
Services billed
1,555

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
ImbruvicaIbrutinib34$541,285
PomalystPomalidomide12$202,775
VenclextaVenetoclax11$143,285
EliquisApixaban69$69,306
Abiraterone Acetate22$67,052
XareltoRivaroxaban37$51,011
Imatinib Mesylate18$36,948
EntrestoSacubitril/Valsartan16$27,834
Enoxaparin Sodium17$8,987
Megestrol Acetate44$4,724
Ondansetron Hcl40$3,542
Fentanyl37$3,247
Letrozole117$2,518
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen63$1,300
Morphine Sulfate ErMorphine Sulfate31$1,297

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Pharmacyclics LLC, An Abbvie CompanyImbruvica$17,450$541,28534 claims
E.r. Squibb & Sons, L.L.C.Pomalyst$1,336$202,77512 claims
AbbVieVenclexta$113$143,28511 claims
PfizerEliquis$3,513$69,30669 claims
Johnson & JohnsonXarelto$726$51,01137 claims
NovartisEntresto$1,050$27,83416 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 53 medical oncology providers in Kentucky.

Other medical oncology in Paducah

See the full list for Kentucky

Where these figures come from

Is this you, or does something look wrong? →